Companies Like Galapagos (AMS:GLPG) Are In A Position To Invest In Growth
Aug 11
GLPG Share Price Performance
€27.38
4.60 (20.19%)
Price €27.38
Share Price€27.38
GLPG Community Narratives
There are no narratives available yet.
Galapagos NV Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 23, 2025
- Earnings per share (EPS)
- -4.38
- Gross Margin
- 39.41%
- Net Profit Margin
- -104.66%
- Debt/Equity Ratio
- 0%
Galapagos NV Competitors
Snowflake Analysis
About GLPG
- Founded
- 1999
- Employees
- 558
- CEO
- WebsiteView website
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Market Insight
This week, we’re going to look at the U.S. regulatory changes, how adoption has been trending, and one of the risks with the ETFs. If you want some exposure to Bitcoin, at the end, we’ll show you some different ways you can position your portfolio accordingly.
Continue reading
Belgian Market Performance
- 7 Days: 1.5%
- 3 Months: 2.3%
- 1 Year: 8.0%
- Year to Date: 9.7%
The market is up 1.5% over the last week, with the Consumer Staples sector leading the way, up 2.5%. In the last year, the market has climbed 8.0%. Looking forward, earnings are forecast to grow by 14% annually. Market details ›